Rocuronium Br (Rocuronium Br)
Overview of Rocuronium Br
Rocuronium (Br) is a non-depolarizing skeletal muscle rexalant. Rocuronium (Br) is used as an adjunct to anaesthesia. Rocuronium (Br) is a competitive neuromuscular blocking agent. It affects the transmission at the neuromuscualr junction. Rocuronium is an injectable, nondepolarizing neuromuscular blocking drug. It was developed out of a need for an agent with a rapid onset and short duration of action, and a low risk of side effects. Rocuronium's onset of action is comparable to that of succinylcholine, but its duration of action is significantly longer. Compared with other nondepolarizing agents, rocuronium has a similar side effect profile but a more rapid onset of action. Rocuronium was approved by the FDA in March 1994.
Indication of Rocuronium Br
Rocuronium Br is primarily indicated in conditions like Adjunct to anesthesia, Muscle relaxation (intermediate duration) during intensive care, Muscle relaxation (intermediate duration) for surgery or intubation, Muscular spasm.
Contraindication of Rocuronium Br
No data regarding the contra indications of Rocuronium (Br) is available.
Side Effects of Rocuronium Br
The symptomatic adverse reactions produced by Rocuronium (Br) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, Vomiting, Tachycardia, Rashes, Pruritus, Cardiac arrhythmias, Edema, Bronchospasm, Hypertension, Hiccups, Transient hypotension.
Precautions of Rocuronium Br
Rocuronium should be used with caution in patients with impaired kidney or liver function.